Tocilizumab, an inhibitory IL-6R antibody, that is approved for rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, and Crohn's disease [49–52], inhibits IL-6 signaling. This evidence concerns the gene IL6R and juvenile idiopathic arthritis.